Arrakis Therapeutics
http://arrakistx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arrakis Therapeutics
Amgen, J&J, Takeda R&D Heads On The Era Of Human Data, Treating Disease Earlier
Big pharma R&D leaders discuss the confluence of technology and biotech driving insights into biology and how industry is doing in terms of identifying patients earlier in disease.
Big Pharma Deal Hunters Target RNA Approaches In Race To Build Best Platforms
The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind.
J&J Jumps On RNA-Based Small Molecules Train In Pact With Remix
Deal Snapshot: The deal, with an upfront payment of $45m, is the latest of several involving large biopharma companies and smaller firms focused on small molecule drugs based on RNA biology.
Amgen Rebuilt R&D Platform To Focus On Speed And Access
The company explained during its recent business review how its R&D organization is pursuing the strategic objectives of improving success rates, reducing cycle times and enabling access to novel drugs.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools